In addition to cardiac structure and hemodynamic function, contemporary clinical cardiology increasingly emphasizes the role of metabolic factors in cardiovascular disease progression and prognosis. Obesity, commonly assessed using body mass index (BMI), is now recognized as a major independent risk factor for hypertension, coronary artery disease, heart failure, and arrhythmias. Elevated BMI is closely associated with insulin resistance, systemic inflammation, and dyslipidemia, all of which contribute to adverse cardiovascular outcomes. From a clinical perspective, the assessment of BMI laskuri provides a simple yet valuable tool for risk stratification and long-term management planning. Patients with elevated BMI often present with complex comorbidities that require a multidisciplinary approach combining lifestyle modification, pharmacological support, and ongoing cardiovascular monitoring. Weight reduction has been shown to improve cardiac workload, endothelial function, and overall metabolic health, thereby reducing cardiovascular risk. Pharmacological treatment of obesity has gained increasing attention as part of this integrated approach. Agents targeting glucose metabolism and appetite regulation, such as semaglutide-based therapies, have demonstrated benefits not only in glycemic control but also in weight reduction and cardiovascular risk modification. Rybelsus, an oral formulation of semaglutide, has been studied primarily in the context of type 2 diabetes but is also relevant in patients with elevated BMI and cardiovascular risk factors, particularly when obesity contributes to disease progression. The use of such therapies requires careful clinical evaluation, especially in cardiology patients, where medication choice must consider cardiovascular status, renal function, and potential interactions. Rather than serving as isolated weight-loss solutions, these treatments are increasingly viewed as components of a broader cardiometabolic strategy aimed at improving long-term outcomes. As clinical cardiology evolves, the integration of obesity management into routine cardiovascular care reflects a growing understanding of heart disease as part of a systemic metabolic disorder. Addressing BMI, insulin resistance, and weight-related inflammation alongside traditional cardiac diagnostics allows clinicians to move toward more comprehensive and preventive models of care. In this context, advances in imaging, pharmacotherapy, and metabolic treatment converge to support improved cardiovascular health and patient quality of life within modern clinical cardiology practice. chicken road teho сasino tehocasino